PHASE 1/2 STUDY OF SINGLE-AGENT ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

EHA 2020: Results of a study investigating zanubrutinib for treatment of relapsed marginal zone lymphoma.